Atorvastatin therapy is associated with greater and faster cerebral hemodynamic response

Brain Imaging and Behavior

Volumn 2, Issue 2, 2008, Pages 94-104

  Xu, Guofan ^a,b   Fitzgerald, Michele E ^a,b   Wen, Zhifei ^b   Fain, Sean B ^b   Alsop, David C ^d,e   Carroll, Timothy ^c   Ries, Michele L ^a,b   Rowley, Howard A ^b   Sager, Mark A ^b   Asthana, Sanjay ^a,b   Johnson, Sterling C ^a,b   Carlsson, Cynthia M ^a,b  

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; Arterial spin labeling; BOLD; Dynamic susceptibility contrast; Event related fMRI; Hemodynamic response

Indexed keywords

ATORVASTATIN; PLACEBO;

ADULT; AGED; ARTICLE; BRAIN; BRAIN BLOOD FLOW; BRAIN PERFUSION; BRAIN REGION; CINGULATE GYRUS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEMODYNAMICS; HUMAN; MALE; OXYGEN BLOOD LEVEL; PARIETAL LOBE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIN LABELING; TASK PERFORMANCE; TEMPORAL CORTEX;

EID: 77949581293     PISSN: 19317557     EISSN: 19317565     Source Type: Journal    
DOI: 10.1007/s11682-007-9019-7     Document Type: Article

References (47)

1. Alsop, D. C., & Detre, J. A. (1996). Reduced transit-time sensitivity in noninvasive magnetic resonance imaging of human cerebral blood flow. Journal Cerebral Blood Flow and Metabolism, 16, 1236-1249.
2. Alsop, D. C., & Detre, J. A. (1998). Multisection cerebral blood flow MR imaging with continuous arterial spin labeling. Radiology, 208, 410-416.
3. Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., Mazziotta, J. C., et al. (2000). Patterns of brain activation in people at risk for Alzheimer's disease. New England Journal of Medicine, 343, 450-456.
4. Braak, H., & Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica (Berlin), 82, 239-259.
5. Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., et al. (2005). Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. Journal of Neuroscience, 25, 7709-7717.
6. Calhoun, V. D., Stevens, M. C., Pearlson, G. D., & Kiehl, K. A. (2004). fMRI analysis with the general linear model: removal of latency-induced amplitude bias by incorporation of hemodynamic derivative terms. Neuroimage, 22, 252-257.
7. Carroll, T. J., Rowley, H. A., & Haughton, V. M. (2003). Automatic calculation of the arterial input function for cerebral perfusion imaging with MR imaging. Radiology, 227, 593-600.
8. Cohen, E. R., Ugurbil, K., & Kim, S. G. (2002). Effect of basal conditions on the magnitude and dynamics of the blood oxygenation level-dependent fMRI response. Journal of Cerebral Blood Flow and Metabolism, 22, 1042-1053.
9. D'Esposito, M., Zarahn, E., Aguirre, G. K., & Rypma, B. (1999). The effect of normal aging on the coupling of neural activity to the bold hemodynamic response. Neuroimage, 10, 6-14.
10. Davis, T. L., Kwong, K. K., Weisskoff, R. M., & Rosen, B. R. (1998). Calibrated functional MRI: mapping the dynamics of oxidative metabolism. Proceedings of the National Academy of Sciences of the United States of America, 95, 1834-1839.
11. Dickerson, B. C., Salat, D. H., Greve, D. N., Chua, E. F., Rand-Giovannetti, E., Rentz, D. M., et al. (2005). Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology, 65, 404-411.
12. Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P., et al. (2001). Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 98, 5856-5861.
13. Fleisher, A. S., Houston, W. S., Eyler, L. T., Frye, S., Jenkins, C., Thal, L. J., et al. (2005). Identification of Alzheimer disease risk by functional magnetic resonance imaging. Archives of Neurology, 62, 1881-1888.
14. Friston, K. J., Mechelli, A., Turner, R., & Price, C. J. (2000). Nonlinear responses in fMRI: the Balloon model, Volterra kernels, and other hemodynamics. Neuroimage, 12, 466-477.
15. Garcia, D., Duhamel, G., & Alsop, D. (2005a). Efficiency of Inversion Pulses for Background Suppressed Arterial Spin Labeling. Magnetic Resonance in Medicine, 54, 366-372.
16. Garcia, D. M., Duhamel, G., & Alsop, D. C. (2005b). Efficiency of inversion pulses for background suppressed arterial spin labeling. Magnetic Resonance in Medicine, 54, 366-372.
17. Haxby, J. V., Ungerleider, L. G., Horwitz, B., Maisog, J. M., Rapoport, S. I., & Grady, C. L. (1996). Face encoding and recognition in the human brain. Proceedings of the National Academy of Sciences of the United States of America, 93, 922-927.
18. Henson, R. N., Price, C. J., Rugg, M. D., Turner, R., & Friston, K. J. (2002). Detecting latency differences in event-related BOLD responses: application to words versus nonwords and initial versus repeated face presentations. Neuroimage, 15, 83-97.
19. Herscovitch, P., & Raichle, M. E. (1985). What is the correct value for the brain-blood partition coefficient for water? Journal of Cerebral Blood Flow and Metabolism, 5, 65-69.
20. Hoge, R. D., Atkinson, J., Gill, B., Crelier, G. R., Marrett, S., & Pike, G. B. (1999). Linear coupling between cerebral blood flow and oxygen consumption in activated human cortex. Proceedings of the National Academy of Sciences of the United States of America, 96, 9403-9408.
21. Johnson, S. C., Schmitz, T. W., Moritz, C. H., Meyerand, M. E., Rowley, H. A., Alexander, A. L., et al. (2006a). Activation of brain regions vulnerable to Alzheimer's disease: the effect of mild cognitive impairment. Neurobiology of Aging, 27, 1604-1612.
22. Johnson, S. C., Schmitz, T. W., Trivedi, M. A., Ries, M. L., Torgerson, B. M., Carlsson, C. M., et al. (2006b). The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. Journal Neuroscience, 26, 6069-6076.
23. Kivipelto, M., Helkala, E. L., Laakso, M. P., Hanninen, T., Hallikainen, M., Alhainen, K., et al. (2002). Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Annals of Internal Medicine, 137, 149-155.
24. Laurienti, P. J., Field, A. S., Burdette, J. H., Maldjian, J. A., Yen, Y. F., & Moody, D. M. (2003). Relationship between caffeine-induced changes in resting cerebral perfusion and blood oxygenation level-dependent signal. AJNR American Journal of Neuroradiology, 24, 1607-1611.
25. Logothetis, N. K., Pauls, J., Augath, M., Trinath, T., & Oeltermann, A. (2001). Neurophysiological investigation of the basis of the fMRI signal. Nature, 412, 150-157.
26. Lundqvist, D., & Litton, J. E. (1998). The averaged Karolinska directed emotional faces - AKDEF. Stockholm, Sweden: Karolinska Institute.
27. Martinez, A. M., & Benavente, R. (1998). The AR face database. CVC Technical Report #24.
28. Masse, I., Bordet, R., Deplanque, D., Al Khedr, A., Richard, F., Libersa, C., et al. (2005). Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. Journal of Neurology Neurosurgery Psychiatry, 76, 1624-1629.
29. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939-944.
30. Miezin, F. M., Maccotta, L., Ollinger, J. M., Petersen, S. E., & Buckner, R. L. (2000). Characterizing the hemodynamic response: effects of presentation rate, sampling procedure, and the possibility of ordering brain activity based on relative timing. Neuroimage, 11, 735-759.
31. O'Driscoll, G., Green, D., & Taylor, R. R. (1997). Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation, 95, 1126-1131.
32. Ogawa, S., Lee, T. M., Kay, A. R., & Tank, D. W. (1990). Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proceedings of the National Academy of Sciences of the United States of America, 87, 9868-9872.
33. Ostergaard, L., Weisskoff, R. M., Chesler, D. A., Gyldensted, C., & Rosen, B. R. (1996). High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magnetic Resonance in Medicine, 36, 715-725.
34. Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Kokmen, E., & Tangelos, E. G. (1997). Aging, memory, and mild cognitive impairment. International Psychogeriatrics, 9(Suppl 1), 65-69.
35. Petrella, J. R., Coleman, R. E., & Doraiswamy, P. M. (2003). Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology, 226, 315-336.
36. Pretnar-Oblak, J., Sabovic, M., Sebestjen, M., Pogacnik, T., & Zaletel, M. (2006). Influence of atorvastatin treatment on L-arginine cerebrovascular reactivity and flow-mediated dilatation in patients with lacunar infarctions. Stroke, 37, 2540-2545.
37. Rombouts, S. A., Goekoop, R., Stam, C. J., Barkhof, F., & Scheltens, P. (2005). Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease. Neuroimage, 26, 1078-1085.
38. Rosen, B. R., Belliveau, J. W., Vevea, J. M., & Brady, T. J. (1990). Perfusion imaging with NMR contrast agents. Magnetic Resonance in Medicine, 14, 249-265.
39. Rother, J., Knab, R., Hamzei, F., Fiehler, J., Reichenbach, J. R., Buchel, C., & Weiller, C. (2002). Negative dip in BOLD fMRI is caused by blood flow-oxygen consumption uncoupling in humans. Neuroimage, 15, 98-102.
40. Rugg, M. D., & Henson, R. N. (2001). Cognitive neuroscience of memory encoding and retrieval. London: Psychology Press.
41. Sager, M. A., Hermann, B., & La Rue, A. (2005). Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. Journal of Geriatric Psychiatry and Neurology, 18, 245-249.
42. Simons, M., Keller, P., Dichgans, J., & Schulz, J. B. (2001). Cholesterol and Alzheimer's disease: is there a link? Neurology, 57, 1089-1093.
43. Smith, C. D., Andersen, A. H., Kryscio, R. J., Schmitt, F. A., Kindy, M. S., Blonder, L. X., et al. (1999). Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology, 53, 1391-1396.
44. ten Dam, V. H., Box, F. M., de Craen, A. J., van den Heuvel, D. M., Bollen, E. L., Murray, H. M., et al. (2005). Lack of effect of pravastatin on cerebral blood flow or parenchymal volume loss in elderly at risk for vascular disease. Stroke, 36, 1633-1636.
45. Trivedi, M. A., Schmitz, T. W., Ries, M. L., Torgerson, B. M., Sager, M. A., Hermann, B. P., et al. (2006). Reduced hippocampal activation during episodic encoding in middle-aged individuals at genetic risk of Alzheimer's disease: a cross-sectional study. BMC Medical, 4, 1.
46. Wu, O., Ostergaard, L., Koroshetz, W. J., Schwamm, L. H., O'Donnell, J., Schaefer, P. W., et al. (2003). Effects of tracer arrival time on flow estimates in MR perfusion-weighted imaging. Magnetic Resonance in Medicine, 50, 856-864.
47. Yamada, M., Huang, Z., Dalkara, T., Endres, M., Laufs, U., Waeber, C., et al. (2000). Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. Journal of Cerebral Blood Flow and Metabolism, 20, 709-717.